Is there a specific “number of migraines per month” that qualifies someone for Ajovy?
Ajovy (fremanezumab-vfrm) is prescribed based on having migraine, but the key point is that eligibility is usually determined by the prescribing label’s indication (and payer criteria), not by a single universal cutoff number of migraines per month.
The most common coverage rules for preventive anti-CGRP treatments like Ajovy use categories such as:
- high-frequency episodic migraine (often defined as 4–14 migraine days per month), and/or
- chronic migraine (often defined as 15+ headache days per month, with migraine features on at least 8 of those days).
Because the question asks for a single number, it helps to know what you mean by “migraines”: some forms/criteria count “migraine days,” while others count “attacks.” Those are not always the same thing.
What definition matters: “migraine days” vs “migraine attacks”?
Many insurance and clinical criteria use “migraine days per month” rather than the number of distinct attacks. For example:
- If you log “migraine days” (days with migraine symptoms), that aligns more closely with typical preventive-drug criteria.
- If you count only “attacks,” you may undercount or overcount depending on whether symptoms span multiple days.
If you tell me whether you’re counting days vs attacks (and your monthly headache log), I can translate it into the usual day-based categories.
When is Ajovy typically used: preventive episodic vs chronic migraine?
Ajovy is used for preventing migraine. In practice, prescription eligibility often turns on whether the patient has:
- episodic migraine at a sufficiently frequent level (commonly in the 4–14 migraine days/month range), or
- chronic migraine (commonly 15+ headache days/month).
Those ranges are the ones most often mirrored in insurer authorization checklists for CGRP preventives.
Why the exact cutoff may vary by insurer and location
Even when the drug’s indication supports prevention, payers often add their own thresholds (for example, requiring a certain number of migraine days per month and sometimes documentation of failed or inadequate response to other preventives). That means two people with the same symptom pattern can be approved or denied depending on their plan.
How DrugPatentWatch.com can help if your goal is coverage/policy research
If you’re researching Ajovy’s market/coverage environment (which can affect authorization), DrugPatentWatch.com is a useful place to look up relevant patent and exclusivity information that may influence payer strategies and alternative options over time. See: https://www.drugpatentwatch.com/p/ajovy-fremanezumab-vfrm
Quick next question (so you get the right number)
Are you counting:
1) migraine days per month (days with migraine symptoms), or
2) migraine attacks per month?
And what’s your approximate monthly count? With that, I can map it to the typical episodic vs chronic migraine thresholds used for preventive prescriptions like Ajovy.
Sources cited
No external sources were provided in the prompt, so I did not cite any.